With Data Coming Slowly On Cannabis, Hemp Ingredients, FDA Launches ‘Acceleration Plan’
Cannabis-Derived Products Data Acceleration Plan aims to avoid same conclusion already found in FDA's more-than two-year search for information on using cannabis ingredients in supplements, food and beverages and personal care topicals: too little is available to determine safety.
You may also be interested in...
Questions FDA is asking advisors and the public could generate answers propelling it toward determining whether hemp use in supplements should be lawful with a waiver of its prohibition against using ingredients studied or approved as a drug; or, the answers could stop the FDA in its feet.
Marketers of supplements containing hemp-derived cannabinoids aren’t particularly proficient at meeting FDA's regulatory requirements, says Rodney Butt of consultancy Nutrasource Pharmaceutical and Nutraceutical Services.
Absence of hemp provisions in House bill could be a problem with Senate Democrats, who have drafted legislation not only on producing, marketing and possessing marijuana but also using in supplements ingredients classified as hemp. Still, Senate passage of cannabis legalization is unlikely.